#Aspirin for primary prevention of cardiovascular disease, part 2

..ASPREE study suggests no benefit from aspirin in primary prevention ASPREE randomized 19,114 healthy people 70 or over (65 or over for African Americans and Hispanics) to receive either 100 milligrams of enteric-coated aspirin or placebo. After an average of almost five years, there was no significant difference in the rate of fatal coronary heart disease, heart attack, stroke, or hospitalization for heart failure. There … Continue reading #Aspirin for primary prevention of cardiovascular disease, part 2

Clinical Influence of Nonadherence With Prophylactic #Aspirin in Preventing #Preeclampsia in High-Risk Pregnancies

..Women with inadequate adherence had higher incidence of early-onset preeclampsia (17% versus 2%; odds ratio [OR], 1.9 [95% CI, 1.1–8.7]; P=0.04), late-onset preeclampsia (41% versus 5%; OR, 4.2 [95% CI, 1.4–19.8]; P=0.04), intrauterine growth restriction (29% versus 5%; OR, 5.8; [95% CI, 1.2–8.3]; P=0.001), preterm delivery (27% versus 10%; OR, 5.2 [95% CI, 1.5–8.7]; P=0.008), and higher likelihood of increase in antihypertensives antenatally (60% versus … Continue reading Clinical Influence of Nonadherence With Prophylactic #Aspirin in Preventing #Preeclampsia in High-Risk Pregnancies

Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement

Patients undergoing total hip replacement (THR) and total knee replacement (TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is unclear which anticoagulant is preferable. Observational data suggest aspirin provides effective VTE prophylaxis.. ..The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin compared with other anticoagulants. Comparable findings were observed for deep vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) and … Continue reading Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement

#Aspirin and #fracture risk: a systematic review and exploratory meta-analysis of observational studies

This review provides insights into the potential for aspirin to preserve bone mineral density (BMD) and reduce fracture risk, building knowledge of the risk-benefit profile of aspirin. ..Aspirin use was associated with a 17% lower odds for any fracture (OR 0.83, 95% CI 0.70 to 0.99; I2=71%; six studies; n=511 390). Aspirin was associated with a higher total hip BMD for women (SMD 0.03, 95% CI −0.02 to … Continue reading #Aspirin and #fracture risk: a systematic review and exploratory meta-analysis of observational studies

Low‐Dose #Aspirin for Primary Prevention of #Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study

..Over a median follow‐up of 11.3 years, low‐dose aspirin use was associated with a trend toward decreased risk of ischemic cardiac death in white participants (adjusted hazard ratio: 0.86; 95% CI, 0.68–1.10), especially in women (adjusted hazard ratio: 0.72; 95% CI, 0.51–1.02), but not in black participants (adjusted hazard ratio: 1.18; 95% CI, 0.98–1.40). Similar trends were observed when the analysis was restricted to high‐risk … Continue reading Low‐Dose #Aspirin for Primary Prevention of #Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study

#Aspirin for primary #prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups

..major adverse cardiovascular events (MACE) ..Aspirin use did not translate into a net clinical benefit adjusted for event-associated mortality risk (mean 0.034%; 95% CI, − 0.18 to 0.25%). There was an interaction for aspirin effect in three patient subgroups: (i) in patients under statin treatment, aspirin was associated with a 12% RRR of MACE (RR 0.88; 95% CI, 0.80–0.96), and this effect was lacking in the … Continue reading #Aspirin for primary #prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). ..The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 95% CI, … Continue reading Ticagrelor with or without Aspirin in High-Risk Patients after PCI